Pancreas-Targeted LNP Development

Pancreas-Targeted LNP Development

BOC Sciences provides customized pancreas-targeted lipid nanoparticle (LNP) development, integrating lipid design, targeting ligand engineering, formulation optimization, and cellular and in vivo delivery evaluation.

Pancreas-targeted LNPs are designed to improve nucleic acid and other payload delivery to pancreatic tissues and specific pancreatic cell populations. Conventional LNPs frequently exhibit liver-dominant accumulation following systemic administration, limiting their delivery to the pancreas. To address this challenge, researchers have explored ionizable lipid optimization, functional lipid incorporation, protein-associated particle enlargement, and cell-specific ligand conjugation. These approaches offer different mechanisms for improving pancreatic accumulation, cellular uptake, and intracellular payload delivery.

Pancreatic delivery also requires distinguishing between endocrine and exocrine compartments. Islet β cells, acinar cells, ductal cells, pancreatic stromal cells, and tumor-associated immune cells have different biological characteristics and delivery requirements. BOC Sciences provides integrated targeted LNP development, covering lipid screening, targeting ligand synthesis, surface modification, payload encapsulation, formulation optimization, and biological evaluation. We support customized LNP development for mRNA, siRNA, miRNA, plasmid DNA, genome-editing components, proteins, and other research payloads.

Lipid Nanoparticle Delivery to Pancreas DiagramPancreas-Targeted Lipid Nanoparticle Illustration

BOC Sciences Pancreas-Targeted LNP Development Services

Our development services integrate lipid chemistry, surface engineering, nanoparticle formulation, and biological evaluation to address the challenges of pancreatic delivery. Projects can begin with an existing LNP formulation, a candidate targeting ligand, or a defined pancreatic delivery objective. We customize the development strategy according to the intended pancreatic cell population, payload characteristics, and administration route.

Pancreas-Selective Lipid Design and Screening

We investigate how ionizable lipid structures and supporting lipid components influence pancreatic tissue distribution, cellular uptake, and intracellular delivery. Lipid composition is evaluated as an integrated system rather than through isolated structural parameters.

  • Ionizable Lipid Optimization: Compare lipid headgroups, apparent pKa, hydrophobic tail length, branching, and linker structures to identify candidates with favorable pancreatic delivery characteristics. Our LNP ionizable lipid optimization services support structure-guided screening.
  • Helper Lipid and Sterol Selection: Investigate phospholipid identity, sterol structures, cholesterol content, and component ratios to regulate membrane interactions, particle assembly, and payload retention. Our LNP helper lipid optimization services support formulation refinement.
  • Composition-Performance Screening: Compare particle size, surface charge, apparent pKa, encapsulation efficiency, cellular uptake, and pancreas-to-liver expression ratios across candidate formulations.

Pancreatic Cell-Targeting Ligand Engineering and Surface Display

We develop ligand-functionalized LNPs to improve interactions with selected pancreatic cell populations. Ligand selection, receptor accessibility, conjugation chemistry, surface orientation, and ligand density are considered together to establish an appropriate targeting architecture.

  • Peptide Ligand Design: Evaluate receptor-binding peptides, including GLP-1-derived peptide designs for GLP-1 receptor-associated β-cell recognition. Optimize peptide sequence, lipid anchoring, linker structure, and surface accessibility.
  • Antibody and Protein Ligands: Explore antibodies, antibody fragments, and other protein-based recognition components directed toward accessible pancreatic cell-surface markers. Target expression and species differences are considered during ligand selection.
  • Conjugation and Surface Display: Optimize lipid anchors, spacer length, coupling conditions, ligand orientation, and surface density through customized nanoparticle conjugation services.

Payload-Compatible LNP Formulation and Process Optimization

We integrate lipid composition, targeting modifications, and payload characteristics into a formulation strategy designed for the intended pancreatic delivery application. Different payloads require different encapsulation conditions and particle architectures.

  • Payload Encapsulation: Optimize lipid-to-payload ratios, aqueous and organic phases, mixing conditions, and formulation pH for different nucleic acid, protein, and small-molecule structures through customized lipid nanoparticle formulation.
  • Surface Composition Balance: Adjust PEG-lipid content, functional lipid incorporation, and targeting ligand density to balance particle stability with pancreatic cell accessibility.
  • Administration-Route Adaptation: Compare formulation requirements for intravenous administration, intraperitoneal injection, and retrograde intraductal administration. Each route presents different tissue exposure and particle transport conditions.
  • Process Parameter Optimization: Refine lipid concentration, mixing conditions, flow-rate ratios, and post-formulation processing through LNP process optimization.

Physicochemical, Cellular, and In Vivo Evaluation

We evaluate the physicochemical properties of candidate LNPs alongside pancreatic cell uptake and tissue-level delivery performance. This integrated approach helps determine whether improved particle characteristics translate into functional payload delivery.

  • Particle Characterization: Analyze particle size, polydispersity index (PDI), zeta potential, morphology, encapsulation efficiency, and payload integrity using appropriate lipid nanoparticle characterization methods.
  • Pancreatic Cell Uptake: Compare cellular association and internalization in selected β-cell, acinar, ductal, and other pancreatic cell models using nanoparticle cellular uptake testing.
  • Functional Payload Delivery: Evaluate reporter expression, target-gene knockdown, protein expression, or genome-editing outcomes according to the payload and research objective.
  • Tissue-Level Evaluation: Compare pancreatic distribution, cell-type localization, and off-target organ exposure through nanoparticle cellular and in vivo evaluation.

Pancreas-Targeting Strategies for Lipid Nanoparticles

Pancreatic delivery can be improved through several distinct LNP engineering strategies. Some approaches modify the intrinsic lipid composition to influence organ distribution, whereas others introduce additional functional components or targeting ligands to promote pancreatic accumulation and cell recognition. BOC Sciences supports the development and comparison of these strategies according to the intended target and payload.

Strategy 1: Lipid-Engineered LNPs for Pancreatic Delivery

Lipid-engineered LNPs use customized ionizable lipids and supporting lipid components to influence particle assembly, apparent pKa, protein interactions, and tissue distribution. By systematically modifying the lipid composition, researchers can identify formulations with improved pancreatic delivery rather than relying on conventional liver-dominant LNP architectures.

  • Design Approach: Modify ionizable lipid headgroups, apparent pKa, hydrophobic tail length, branching, and linker structures. Screen combinations with helper phospholipids, sterols, and PEG-lipids while evaluating particle size, surface charge, and payload encapsulation.
  • Delivery Mechanism: Changes in lipid composition can influence interactions with biological proteins, tissue-associated barriers, cellular membranes, and intracellular trafficking pathways. The resulting organ distribution must be established experimentally rather than predicted from pKa alone.
  • Use Scenarios: Develop mRNA-LNPs for pancreatic protein expression, siRNA-LNPs for pancreatic gene silencing, and genome-editing formulations for pancreatic cell research.

Research reference: A 2026 ACS Nano study combined lipid screening and ligand conjugation to improve β-cell-directed RNA delivery in experimental models (ACS Nano, 2026).

Strategy 2: Vitamin D3-Incorporating LNPs for Systemic Pancreatic Delivery

Vitamin D3, also known as cholecalciferol, can be incorporated as an additional functional component in LNP formulations. This strategy introduces a biologically active lipid-associated molecule that may contribute to pancreatic tissue recognition through interactions involving the vitamin D receptor (VDR).

  • Design Approach: Incorporate cholecalciferol as a fifth formulation component alongside an ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid. Optimize its molar fraction and compatibility with the other lipid components to maintain particle integrity and payload encapsulation.
  • Delivery Mechanism: Vitamin D3-containing LNPs have been investigated for systemic pancreatic delivery following intravenous administration. The proposed mechanism involves VDR-associated pancreatic recognition and uptake, although receptor involvement should be evaluated for each formulation and experimental model.
  • Use Scenarios: Develop systemically administered mRNA-LNPs for pancreatic protein expression, plasmid DNA delivery, and circular RNA delivery in pancreatic tissue research.

Research reference: A 2025 Advanced Materials study reported a cholecalciferol-containing five-component LNP for systemic pancreatic mRNA delivery, achieving over 99% pancreatic selectivity in reported animal experiments (Advanced Materials, 2025).

Strategy 3: Protein-Associated LNPs for Size-Dependent Pancreatic Accumulation

Protein-associated LNPs exploit interactions with proteins in the biological environment to modify particle size and tissue distribution. In this approach, protein assembly can increase the apparent particle size after administration, allowing the resulting particles to interact differently with organ-associated filtering barriers and cellular uptake pathways.

  • Design Approach: Select lipid compositions that support appropriate protein association while maintaining payload retention and particle integrity. Evaluate particle size before and after exposure to biological fluids, together with the composition of associated proteins.
  • Delivery Mechanism: Protein-associated particle enlargement can promote pancreas-selective accumulation through size-dependent filtration by the pancreatic capsule. Subsequent receptor-mediated endocytosis can contribute to cellular uptake. These effects depend on the specific particle-protein interactions and should not be assumed for every protein-associated LNP.
  • Use Scenarios: Explore systemically administered LNPs for pancreatic mRNA expression, genome-editing research, and delivery of immunomodulatory payloads to pancreatic tissues.

Research reference: A 2026 Nature study reported protein-associated LNP enlargement for pancreatic accumulation and receptor-mediated uptake, demonstrating pancreatic genome editing with Cas9 mRNA and sgRNA (Nature, 2026).

Strategy 4: Ligand-Conjugated LNPs for β-Cell Targeting

Ligand-conjugated LNPs display receptor-binding peptides, antibodies, or other recognition components on the particle surface to improve interactions with pancreatic β cells. This strategy adds a cell-recognition layer to the underlying LNP formulation, helping distinguish β-cell-directed delivery from general pancreatic tissue accumulation.

  • Design Approach: Select ligands recognizing accessible β-cell-associated receptors or surface markers. GLP-1-derived peptides targeting the glucagon-like peptide-1 receptor (GLP-1R) represent one research direction. Antibody-based recognition of β-cell-enriched markers provides another design option. Optimize lipid anchors, spacer length, ligand orientation, and surface density.
  • Delivery Mechanism: Surface-displayed ligands interact with corresponding receptors or recognition sites on β-cell membranes, promoting particle association and receptor-mediated internalization. Successful targeting also requires sufficient intracellular payload release.
  • Use Scenarios: Develop mRNA-LNPs for β-cell protein expression, siRNA-LNPs for gene silencing, and other nucleic acid delivery systems for diabetes-related pancreatic research.

Research reference: A 2026 Cell Reports Medicine study investigated GLP-1-derived peptide-conjugated LNPs for β-cell mRNA delivery in mouse models (Cell Reports Medicine, 2026).

Which Pancreas-Targeting Strategy Fits Your Program?

Tell us the cell population you need to reach, your payload, and the route you can use. BOC Sciences will compare the feasible strategies and propose a screening plan with defined decision points.

Supported Payloads for Pancreas-Targeted LNPs

Pancreas-targeted LNPs can accommodate different payload classes depending on the intended biological mechanism and target cell population. Nucleic acids are commonly investigated for gene expression, gene silencing, and genome editing, while proteins, peptides, and small molecules offer additional possibilities for pancreatic research. BOC Sciences supports payload-specific encapsulation and formulation development, with particle composition and evaluation methods matched to the physicochemical properties of each cargo.

Payload TypeSupported Uses & Pancreas-Targeted LNP Development ConsiderationsRequest Information
Pancreas-Targeted LNP for mRNADesigned for pancreatic protein expression, β-cell gene modulation, and delivery of immunomodulatory or regenerative factors. Development focuses on mRNA integrity, encapsulation efficiency, translation activity, and cell-specific expression. Supported by our lipid nanoparticles for mRNA delivery platform.Inquiry
Pancreas-Targeted LNP for siRNASuitable for gene-silencing studies involving β cells, pancreatic immune cells, and other pancreatic cell populations. Development evaluates siRNA encapsulation, intracellular release, target-gene knockdown, and cell-specific delivery, supported by our lipid nanoparticles for siRNA delivery services.Inquiry
Pancreas-Targeted LNP for miRNAApplicable to studies of pancreatic gene networks, β-cell function, inflammation, and metabolic signaling. Formulation work considers RNA stability, encapsulation, intracellular availability, and changes in target-gene expression, drawing on our lipid nanoparticles for miRNA delivery experience.Inquiry
Pancreas-Targeted LNP for Plasmid DNADesigned for pancreatic gene expression and genetic construct delivery. Development evaluates DNA integrity, encapsulation, particle stability, cellular uptake, and nuclear delivery requirements. Supported by our lipid nanoparticles for pDNA delivery services.Inquiry
Pancreas-Targeted LNP for circRNASuitable for research requiring sustained protein expression in pancreatic tissues. Development considers circular RNA integrity, encapsulation behavior, particle stability, and expression duration in the intended pancreatic cell models, supported by our lipid nanoparticles for circRNA delivery platform.Inquiry
Pancreas-Targeted LNP for saRNADesigned for self-amplifying RNA expression studies in pancreatic cell populations. Formulation development considers the relatively large RNA structure, encapsulation efficiency, particle stability, and expression kinetics. Supported by our lipid nanoparticles for saRNA delivery platform.Inquiry
Pancreas-Targeted LNP for ASOApplicable to splice-modifying and transcript-regulating oligonucleotide research in pancreatic cells. Development focuses on oligonucleotide loading, nuclease protection, intracellular trafficking, and target-specific activity, supported by our lipid nanoparticles for ASO delivery services.Inquiry
Pancreas-Targeted LNP for CRISPR ComponentsDesigned for pancreatic gene-editing research using Cas9 mRNA and sgRNA, or other compatible editing components. Development evaluates payload compatibility, co-encapsulation, RNA integrity, intracellular release, and editing outcomes in the intended pancreatic cell population. Supported by our lipid nanoparticles for CRISPR RNP delivery capabilities.Inquiry
Pancreas-Targeted LNP for Protein and PeptideApplicable to enzymes, signaling proteins, and bioactive peptides intended for pancreatic delivery research. Formulation work emphasizes loading compatibility, aggregation control, payload retention, and preserved biological activity, supported by our protein encapsulation and peptide encapsulation in LNPs services.Inquiry
Pancreas-Targeted LNP for Small MoleculesDesigned for hydrophobic, amphiphilic, or ionizable small molecules studied in pancreatic metabolism, inflammation, and cell signaling. We evaluate drug-lipid compatibility, loading method, retention during surface modification, and release behavior, supported by lipid nanoparticles for small-molecule delivery.Inquiry
Pancreas-Targeted LNP for Co-DeliverySuitable for projects requiring the combined delivery of multiple nucleic acids or different payload classes. Development evaluates component compatibility, loading sequence, encapsulation balance, particle stability, and the functional relationship between co-delivered components. Supported by our lipid nanoparticles for co-delivery platform.Inquiry
Need a Pancreas-Targeted LNP for Your Specific Payload?

Tell us your payload, target pancreatic cell population, and delivery objective. BOC Sciences can help evaluate compatible lipid compositions, targeting modifications, and encapsulation strategies for your project.

Our Pancreas-Targeted LNP Development Workflow

Pancreas-targeted LNP projects require coordinated optimization of particle composition, targeting architecture, administration route, and biological evaluation. Projects can begin with an existing LNP formulation, a candidate targeting ligand, or a defined pancreatic delivery objective. We organize development into four practical stages and refine the strategy as formulation and biological evidence becomes available.

Pancreatic target and payload requirement discussion

1Define the Pancreatic Target, Payload, and Delivery Objective

We review the intended pancreatic target, payload type, baseline LNP formulation if available, and desired biological outcome. An important first step is distinguishing between organ-level pancreatic accumulation and delivery to a specific cell population, such as β cells, acinar cells, ductal cells, or tumor-associated immune cells. We also consider whether the objective involves protein expression, gene silencing, genome editing, or modulation of pancreatic cell function. These inputs define the starting materials, comparator models, and evaluation endpoints.

Lipid composition and targeting architecture selection

2Select Lipid Composition, Targeting Ligand, and Administration Route

We propose candidate ionizable lipids, helper phospholipids, sterols, and PEG-lipid compositions according to the intended pancreatic target. When cell-specific recognition is required, we evaluate suitable peptide, antibody, or protein-based ligands and corresponding surface attachment strategies. The administration route is also considered during formulation planning, including intravenous administration for systemic distribution, intraperitoneal injection for pancreatic exposure, or retrograde intraductal administration for direct pancreatic delivery research. Formulation ratios are refined through LNP lipid ratio optimization services, with appropriate non-targeted and alternative-composition controls.

LNP formulation and characterization

3Formulate and Characterize Candidate LNPs

Candidate formulations are prepared under controlled mixing conditions and compared for particle size, PDI, zeta potential, morphology, encapsulation efficiency, and payload integrity. Microfluidic preparation can be considered when controlled mixing and formulation reproducibility are important, supported by our microfluidic LNP production services. We also evaluate ligand incorporation and particle stability before and after exposure to relevant biological media. Candidates are advanced according to predefined project-specific particle and payload acceptance criteria rather than relying on a single characterization result.

Pancreatic cellular and in vivo delivery evaluation

4Evaluate Pancreatic Distribution and Functional Payload Delivery

Selected candidates are evaluated in appropriate pancreatic cell models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression, target-gene knockdown, or genome-editing activity. In vivo evaluation can compare pancreatic accumulation with liver, spleen, and other organ distribution, followed by cell-type-resolved analysis to determine whether the payload reaches the intended pancreatic compartment. We can also incorporate nanoparticle intracellular localization detection and nanoparticle in vivo imaging to investigate tissue distribution and intracellular trafficking. Findings are summarized as comparative data with documented formulation tradeoffs and suggested next experiments.

What Pancreas-Targeted LNP Development Challenges Do We Solve?

A pancreas-targeted LNP may show favorable particle characteristics yet still accumulate primarily in the liver, distribute unevenly across pancreatic compartments, or deliver insufficient functional payload. We investigate formulation and biological factors together to identify the step limiting pancreatic delivery and establish a focused optimization strategy.

✔ Low Pancreatic LNP Accumulation, High Liver Uptake

Conventional systemic LNPs frequently exhibit liver-dominant distribution because of interactions with circulating proteins, hepatic clearance pathways, and tissue-specific uptake mechanisms. This can leave insufficient payload available for pancreatic delivery. We compare ionizable lipid structures, apparent pKa, sterol composition, PEG-lipid density, and particle size to investigate formulation-dependent organ distribution. Nanoparticle in vivo distribution analysis can help establish pancreatic-to-liver accumulation ratios and determine whether formulation changes improve tissue selectivity.

✔ Limited LNP Access to Pancreatic Islets

Pancreatic islets represent a relatively small and spatially distributed tissue compartment surrounded by specialized microvasculature and extracellular structures. Therefore, whole-pancreas accumulation does not necessarily indicate effective β-cell delivery. We investigate particle size, surface properties, administration route, and receptor-binding ligand accessibility to improve islet exposure. Cellular uptake and tissue-localization measurements are used together to distinguish general pancreatic accumulation from delivery to the intended endocrine cell population.

✔ Uneven LNP Delivery Across Pancreatic Compartments

The pancreas contains endocrine islets and a much larger exocrine compartment composed primarily of acinar and ductal structures. LNPs may accumulate in pancreatic tissue but preferentially enter one cell population rather than the intended target. We use cell-type-resolved imaging, flow cytometry, and appropriate marker-based analysis to compare uptake and functional expression across pancreatic compartments. The resulting data help guide adjustments to lipid composition, ligand density, and administration-compatible formulation parameters. Our nanoparticle in vitro evaluation services support comparative cellular assessment.

✔ Limited Payload Release from Pancreatic LNPs

Particle uptake does not necessarily result in functional cytosolic delivery. Internalized LNPs may remain trapped in endosomal compartments or undergo lysosomal degradation before the payload becomes available. We investigate ionizable lipid structure, apparent pKa, helper lipid composition, and intracellular trafficking to identify potential release limitations. Changes in cellular uptake are interpreted alongside functional payload readouts, supported by our LNP endosomal escape evaluation services and nanoparticle surface charge analysis.

Facing Low Pancreatic Delivery or Insufficient β-Cell Uptake?

Share your current lipid composition, targeting strategy, payload, and evaluation results. BOC Sciences can help investigate the limiting formulation parameters and establish a focused pancreatic delivery optimization plan.

Applications of Pancreas-Targeted LNPs

Pancreas-targeted LNPs provide opportunities for nucleic acid delivery across endocrine and exocrine pancreatic research. Their applications include β-cell gene modulation, acinar cell delivery, pancreatic genome editing, and tumor microenvironment modulation. BOC Sciences supports customized LNP development for these research directions, including payload selection, lipid and ligand engineering, formulation optimization, and functional delivery evaluation.

01

β-Cell Gene Modulation and Diabetes Research

  • β-Cell Gene Expression: Develop mRNA-LNPs for the expression of proteins involved in β-cell function, insulin signaling, and cellular protection. GLP-1 receptor-binding peptide-conjugated LNPs have been investigated for β-cell-directed mRNA delivery, including studies using mouse and human β-cell systems.
  • Immune and Inflammatory Modulation: Explore mRNA, siRNA, or miRNA delivery to investigate inflammatory signaling and β-cell susceptibility to immune-mediated damage. A 2026 Cell Reports Medicine study reported β-cell-directed PD-L1 mRNA delivery and investigated its effects in autoimmune diabetes mouse models (Cell Reports Medicine, 2026).
02

Acinar Cell Delivery and Exocrine Pancreas Research

  • Acinar Cell Gene Expression: Develop LNPs carrying Cre mRNA, reporter mRNA, or other expression constructs to investigate gene function in pancreatic acinar cells. Delivery efficiency should be assessed separately from whole-pancreas accumulation.
  • Exocrine Pancreas Gene Editing: Explore Cas9 mRNA and sgRNA delivery for gene modification in acinar cell models. A 2026 Nanomedicine: Nanotechnology, Biology and Medicine study investigated retrograde intraductal LNP administration and reported approximately 47% acinar cell transfection in mouse models, demonstrating the potential of route-specific pancreatic delivery (Nanomedicine, 2026).
03

Pancreatic Gene Editing and Inherited Disease Research

  • Pancreatic Genome Editing: Develop LNPs co-delivering Cas9 mRNA and sgRNA to investigate targeted gene disruption or correction in pancreatic cells. Published research has demonstrated pancreatic genome editing using protein-associated, pancreas-enriched LNP formulations.
  • Inherited Pancreatic Disease Models: Explore gene-editing payloads targeting genetic alterations associated with inherited pancreatitis and other pancreatic disorders. Development focuses on editing-component compatibility, target-cell delivery, editing efficiency, and the distribution of editing activity across pancreatic compartments.
04

Pancreatic Tumor Microenvironment Modulation

  • Immunomodulatory mRNA Delivery: Develop LNPs carrying IL-12 and other cytokine-encoding mRNAs to investigate immune-cell activation and remodeling of the pancreatic tumor microenvironment. A 2025 Journal of Controlled Release study reported intraperitoneally administered IL-12 mRNA-LNPs that delivered mRNA to pancreatic tissue and immune cells in orthotopic pancreatic ductal adenocarcinoma models (Journal of Controlled Release, 2025).
  • Tumor-Associated Immune Modulation: Explore cytokine and other immunomodulatory payloads to investigate macrophage activity, T-cell responses, and tumor-associated immune signaling. Pancreatic tumor-targeted delivery requires separate consideration of tumor accumulation, stromal penetration, and immune-cell localization rather than assuming that normal pancreatic tissue targeting provides equivalent tumor delivery.
Develop a Pancreas-Targeted LNP for Your Research Application

Tell us your intended pancreatic target, payload, and research objective. Drawing on published delivery strategies and our formulation capabilities, BOC Sciences can help design, synthesize, formulate, and evaluate customized pancreas-targeted LNPs.

Why Choose BOC Sciences for Pancreas-Targeted LNP Development?

Specialized LNP Development Expertise

We integrate lipid chemistry, nanoparticle formulation, surface engineering, and biological evaluation to address complex pancreatic delivery requirements. Our development approach considers organ-level accumulation and cell-specific delivery as separate performance objectives, helping researchers select appropriate formulation strategies for different pancreatic targets.

Comprehensive Lipid Raw Materials

We support pancreatic LNP development with a range of lipid components, including ionizable lipids, helper phospholipids, sterols, PEG-lipids, and functional lipids. Different lipid structures can be selected and combined according to the required particle characteristics, payload compatibility, and targeting mechanism.

Integrated LNP Characterization and Evaluation Services

Our evaluation capabilities cover particle size, PDI, zeta potential, morphology, encapsulation efficiency, payload integrity, cellular uptake, and in vivo distribution. Combining physicochemical and biological readouts helps determine whether formulation improvements translate into better pancreatic delivery and functional payload availability.

Custom Synthesis of Lipids and Targeting Ligands

We support customized synthesis of ionizable lipids, functional lipid components, peptide ligands, and other targeting materials. Our custom synthesis capabilities help researchers obtain components with specific structural features for formulation screening, surface conjugation, and pancreatic cell-targeting studies.

LNP Surface Modification and Formulation Optimization

We optimize PEG-lipid content, ligand attachment, surface density, spacer structure, lipid ratios, and formulation parameters to improve particle stability and target-cell accessibility. Our nanoparticle surface functionalization services and LNP PEG-lipid optimization services support customized surface engineering and iterative formulation development.

FAQs

What distinguishes pancreas-targeted LNPs from conventional LNPs?

Pancreas-targeted lipid nanoparticles are engineered to improve payload delivery to pancreatic tissues or specific pancreatic cell populations. Unlike conventional LNPs, which frequently exhibit liver-dominant accumulation after systemic administration, these formulations use tailored ionizable lipids, functional lipid components, or surface-displayed targeting ligands to influence tissue distribution and cellular uptake. Some designs aim for whole-pancreas enrichment, while others focus on endocrine cells such as β cells or exocrine cells such as acinar cells. Their performance depends on lipid composition, particle characteristics, administration route, and the biological properties of the intended target.

Several engineering strategies can be explored to improve pancreatic LNP delivery. Lipid-engineered LNPs use optimized ionizable and helper lipid structures to influence tissue distribution. Vitamin D3-incorporating LNPs introduce cholecalciferol as an additional formulation component for systemic pancreatic delivery research. Protein-associated LNPs exploit protein interactions and size-dependent accumulation mechanisms, whereas ligand-conjugated LNPs use receptor-binding peptides or other recognition components to promote β-cell uptake. These strategies address different delivery barriers and should be selected according to the intended pancreatic target, payload, and administration route.

β-cell-targeted LNPs can be developed by displaying receptor-binding peptides, antibodies, or other recognition components on the particle surface. GLP-1-derived peptides targeting the glucagon-like peptide-1 receptor (GLP-1R) represent one investigated approach. Development involves selecting an accessible target, optimizing ligand attachment chemistry, spacer length, orientation, and surface density, and maintaining particle stability. Targeting performance should be evaluated using β-cell-specific uptake measurements, cellular localization, and functional payload readouts such as reporter expression or target-gene modulation. Whole-pancreas accumulation alone cannot establish successful β-cell delivery.

The main administration routes explored for pancreatic LNP delivery include intravenous, intraperitoneal, and retrograde intraductal administration. Intravenous injection is investigated for systemic distribution using organ-tropic or ligand-functionalized formulations. Intraperitoneal administration can provide pancreatic exposure through regional distribution and has been explored in pancreatic tissue and tumor-associated delivery research. Retrograde intraductal administration provides a more direct route for pancreatic ductal access and has been investigated for exocrine pancreatic cell delivery. Route selection depends on the intended pancreatic compartment, payload, experimental model, and desired distribution profile.

BOC Sciences supports customized pancreatic LNP formulation for multiple payload classes, including mRNA, siRNA, miRNA, plasmid DNA, circular RNA, self-amplifying RNA, antisense oligonucleotides, and CRISPR-associated components. Protein, peptide, and small-molecule encapsulation can also be explored according to payload properties and formulation compatibility. Development considerations include molecular size, charge, hydrophobicity, structural integrity, encapsulation efficiency, and intracellular release requirements. We can help select suitable lipid compositions, optimize encapsulation conditions, and evaluate particle characteristics and functional delivery in relevant pancreatic cell models and systems.

* Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Online Inquiry
Verification code